Sarepta Therapeutics Reports Strong 2024 Performance, Exceeds Guidance
Generado por agente de IAMarcus Lee
lunes, 13 de enero de 2025, 12:34 pm ET1 min de lectura
DOUG--
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, reported preliminary* fourth quarter and full-year 2024 net product revenue, marking a significant year for the company and its patients. The company's exceptional performance was highlighted by Doug Ingram, president and chief executive officer, who stated, "2024 marked the most significant year to date for Sarepta and for the patients we serve."
The company's total net product revenue for the fourth quarter of 2024 was $638.2 million, representing a 75% year-over-year growth. This impressive figure was driven by the robust performance of ELEVIDYS, which grew by a very robust 112% over the prior sequential quarter, overachieving guidance by more than $60 million. The company's 2024 total net product revenue grew by 56% over 2023, demonstrating a strong track record of execution and growth.
ELEVIDYS, a single-dose, adeno-associated virus (AAV)-based gene transfer therapy, played a significant role in the company's success. The drug, indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age, generated $384.2 million in net product revenue for the fourth quarter and $820.8 million for full-year 2024. Despite the strong launch of ELEVIDYS, Sarepta's PMO franchise continued to perform and grow year-over-year, generating $254.0 million and $967.2 million in net product revenue for the fourth quarter and full-year of 2024, respectively.
The company's preliminary year-end 2024 cash, cash equivalents, restricted cash, and investments balance was approximately $1.5 billion. This substantial cash position reflects the company's strong financial health and ability to invest in its pipeline and future growth.
Sarepta Therapeutics reiterated its 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion, indicating its confidence in maintaining its growth trajectory. The company's exceptional performance in 2024, driven by the strong launch of ELEVIDYS and the continued growth of its PMO franchise, positions it well for continued success in the coming years.
In conclusion, Sarepta Therapeutics' preliminary* fourth quarter and full-year 2024 net product revenue report highlights the company's strong performance and growth potential. With a robust pipeline, a diverse portfolio of products, and a track record of execution, Sarepta Therapeutics is well-positioned to continue delivering value to its shareholders and patients in the years to come.
SRPT--
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, reported preliminary* fourth quarter and full-year 2024 net product revenue, marking a significant year for the company and its patients. The company's exceptional performance was highlighted by Doug Ingram, president and chief executive officer, who stated, "2024 marked the most significant year to date for Sarepta and for the patients we serve."
The company's total net product revenue for the fourth quarter of 2024 was $638.2 million, representing a 75% year-over-year growth. This impressive figure was driven by the robust performance of ELEVIDYS, which grew by a very robust 112% over the prior sequential quarter, overachieving guidance by more than $60 million. The company's 2024 total net product revenue grew by 56% over 2023, demonstrating a strong track record of execution and growth.
ELEVIDYS, a single-dose, adeno-associated virus (AAV)-based gene transfer therapy, played a significant role in the company's success. The drug, indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age, generated $384.2 million in net product revenue for the fourth quarter and $820.8 million for full-year 2024. Despite the strong launch of ELEVIDYS, Sarepta's PMO franchise continued to perform and grow year-over-year, generating $254.0 million and $967.2 million in net product revenue for the fourth quarter and full-year of 2024, respectively.
The company's preliminary year-end 2024 cash, cash equivalents, restricted cash, and investments balance was approximately $1.5 billion. This substantial cash position reflects the company's strong financial health and ability to invest in its pipeline and future growth.
Sarepta Therapeutics reiterated its 2025 full-year total net product revenue guidance of $2.9 to $3.1 billion, indicating its confidence in maintaining its growth trajectory. The company's exceptional performance in 2024, driven by the strong launch of ELEVIDYS and the continued growth of its PMO franchise, positions it well for continued success in the coming years.
In conclusion, Sarepta Therapeutics' preliminary* fourth quarter and full-year 2024 net product revenue report highlights the company's strong performance and growth potential. With a robust pipeline, a diverse portfolio of products, and a track record of execution, Sarepta Therapeutics is well-positioned to continue delivering value to its shareholders and patients in the years to come.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios